biostudies-literatureUnknown156(12)van der Kruijssen DEW<h4>Importance</h4>The role of primary tumor resection (PTR) in synchronous patients with metastatic colorectal cancer (mCRC) who had unresectable metastases and few or absent symptoms of their primary tumor is unclear. Studying subgroups with low postoperative mortality may identify patients who potentially benefit from PTR.<h4>Objective</h4>To determine the difference in 60-day mortality between patients randomized to systemic treatment only vs PTR followed by systemic treatment, and to explore risk factors associated with 60-day mortality.<h4>Design, setting, and participants</h4>CAIRO4 is a randomized phase 3 trial initiated in 2012 in which patients with mCRC were randomized to systemic treatment only or PTR followed by systemic treatment with palliative intent. This multicenter studyJAMA surgery1093-1101https://www.ebi.ac.uk/biostudies/studies/S-EPMC8495602biostudies-literatureSixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial.PMC8495602Jakobsen HLde Groot JWBYilmaz MKBaeten CIMKuenen BCLeijtens JWAVles WJTrajkovic MKoopman MBakker SDVuylsteke RJCLMvan Arkel KLutke Holzik MFVerheul HMWKurk SHelgason HHTanis PJvan Tilburg MWAvan Cruijsen HLeclercq WKGvan Breugel EAvan de Wouw AJYde Vos AICense HALoosveld OJLWegdam JANielsen JDBrosens RPMKuijer Pde Hingh IHJTde Gier MJvan Duijvendijk PFromm AGSchreurs WHHReijnders KVogelaar FJJvan Dodewaard JMvan Acker GJDvan Grevenstein WMUHHaberkorn BCMNieboer P't Lam-Boer JCAIRO4 Working GroupVerseveld MBleeker WAPeeters KCMJElias SGHamberg Pvan Hoogstraten MJde Jongh FEVan Riel JMGHAvan der Schelling GPSchlesinger NHBosscha Kvan Rooijen KLGerhards MFTemizkan Mvan der Deure WMde Graaf EJRden Boer FCGelderblom AJHVos AHvan Westreenen HLvan der Kruijssen DEWvan de Ven AWHOulad Hadj JPronk AHess DAHendriks MPvan der Hoeven JABvan Leeuwen-Snoeks LLKjær MLRietbroek RCMol LSommeijer DWSeiersen Mvan der Harst EAltaf Rden Boer MOSimkens LHJConsten ECJPultrum BBHoekstra RVincent Jde Widt-Levert LMVink GRLiposits GICreemers GJSchut HPunt CJAde Wilt JHWKerver EDPetersen LNWasowicz-Kemps DfalseSixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial.<h4>Importance</h4>The role of primary tumor resection (PTR) in synchronous patients with metastatic colorectal cancer (mCRC) who had unresectable metastases and few or absent symptoms of their primary tumor is unclear. Studying subgroups with low postoperative mortality may identify patients who potentially benefit from PTR.<h4>Objective</h4>To determine the difference in 60-day mortality between patients randomized to systemic treatment only vs PTR followed by systemic treatment, and to explore risk factors associated with 60-day mortality.<h4>Design, setting, and participants</h4>CAIRO4 is a randomized phase 3 trial initiated in 2012 in which patients with mCRC were randomized to systemic treatment only or PTR followed by systemic treatment with palliative intent. This multicenter study2021-01-01T00:00:00Z2021 Dec2026-05-08T01:59:13.106Z2024-11-08T20:01:30.203ZS-EPMC84956023461333910.1001/jamasurg.2021.4992